CoreCap Advisors
AKTS icon

CoreCap Advisors’s Aktis Oncology AKTS Stock Holding History

CoreCap Advisors’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-29
Closed -$935 – 3425
2026
Q2 		$935 Buy
+29
New +$596 ﹤0.01% 2710

Other funds holding AKTS

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

CoreCap Advisors's AKTS Position: Q3 2026 in Review

CoreCap Advisors sold out of Aktis Oncology (AKTS) in Q3 2026, closing a stake of 29 shares — an estimated $935 sold.

CoreCap Advisors first reported a position in AKTS in Q2 2026 and held it in 1 quarter. The position peaked at $935 in Q2 2026. 6 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.

  • CoreCap Advisors reported no remaining Aktis Oncology position as of Q3 2026 after selling out during the quarter.
  • CoreCap Advisors sold 29 Aktis Oncology shares in Q3 2026, an estimated $935.
  • CoreCap Advisors first reported a position in Aktis Oncology in Q2 2026 and held it in 1 quarter.
  • CoreCap Advisors's Aktis Oncology position peaked at $935 in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.